ANAPTYSBIO INC's ticker is ANAB and the CUSIP is 032724106. A total of 116 filers reported holding ANAPTYSBIO INC in Q2 2023. The put-call ratio across all filers is 0.97 and the average weighting 0.2%.
Links
Filings
- All filings
- Annual reports (10-K)
- Quarterly reports (10-Q)
- Insider transactions
- Shareholder votes
- Significant ownership
- Events
EDGAR links
External links
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,204,082 | +19.3% | 178,401 | +35.1% | 0.00% | 0.0% |
| Q2 2023 | $2,685,612 | -33.5% | 132,036 | -28.9% | 0.00% | 0.0% |
| Q1 2023 | $4,038,656 | +21.1% | 185,600 | +72.5% | 0.00% | 0.0% |
| Q4 2022 | $3,333,749 | +36.0% | 107,575 | +12.0% | 0.00% | 0.0% |
| Q3 2022 | $2,452,000 | +7.0% | 96,088 | -14.9% | 0.00% | 0.0% |
| Q2 2022 | $2,291,000 | -59.7% | 112,859 | -50.9% | 0.00% | 0.0% |
| Q1 2022 | $5,686,000 | -48.4% | 229,833 | -27.6% | 0.00% | -50.0% |
| Q4 2021 | $11,024,000 | +16.9% | 317,237 | -8.7% | 0.00% | 0.0% |
| Q3 2021 | $9,427,000 | +6.8% | 347,622 | +2.1% | 0.00% | 0.0% |
| Q2 2021 | $8,828,000 | -9.5% | 340,459 | -24.8% | 0.00% | 0.0% |
| Q1 2021 | $9,757,000 | +32.0% | 452,752 | +31.7% | 0.00% | 0.0% |
| Q4 2020 | $7,391,000 | +90.0% | 343,811 | +30.4% | 0.00% | +100.0% |
| Q3 2020 | $3,889,000 | -49.4% | 263,691 | -23.4% | 0.00% | -50.0% |
| Q2 2020 | $7,689,000 | +411.6% | 344,166 | +223.6% | 0.00% | +100.0% |
| Q1 2020 | $1,503,000 | -69.2% | 106,357 | -64.6% | 0.00% | 0.0% |
| Q4 2019 | $4,887,000 | -7.6% | 300,767 | +99.0% | 0.00% | -50.0% |
| Q3 2019 | $5,288,000 | -24.1% | 151,120 | +22.3% | 0.00% | 0.0% |
| Q2 2019 | $6,970,000 | -17.2% | 123,544 | +7.2% | 0.00% | -33.3% |
| Q1 2019 | $8,419,000 | -1.5% | 115,246 | -14.0% | 0.00% | 0.0% |
| Q4 2018 | $8,549,000 | -49.8% | 134,010 | -21.4% | 0.00% | -25.0% |
| Q3 2018 | $17,018,000 | +44.8% | 170,579 | +3.1% | 0.00% | +33.3% |
| Q2 2018 | $11,752,000 | +177.3% | 165,430 | +306.3% | 0.00% | +200.0% |
| Q1 2018 | $4,238,000 | -71.9% | 40,712 | -72.8% | 0.00% | -75.0% |
| Q4 2017 | $15,065,000 | +300.8% | 149,567 | +39.1% | 0.00% | +300.0% |
| Q3 2017 | $3,759,000 | +1257.0% | 107,563 | +829.8% | 0.00% | – |
| Q2 2017 | $277,000 | – | 11,569 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| FRAZIER MANAGEMENT LLC | 3,688,448 | $102,354,000 | 54.68% |
| Novo Holdings A/S | 3,033,504 | $84,180,000 | 8.96% |
| BVF INC/IL | 1,738,600 | $48,246,000 | 8.21% |
| Cormorant Asset Management, LP | 895,626 | $24,854,000 | 3.61% |
| Perceptive Advisors | 881,957 | $24,474,000 | 1.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 100,500 | $2,789,000 | 1.07% |
| ACUTA CAPITAL PARTNERS, LLC | 165,690 | $4,138,000 | 0.98% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 845,746 | $23,469,000 | 0.90% |
| Iguana Healthcare Management, LLC | 50,000 | $1,388,000 | 0.69% |
| Boxer Capital, LLC | 50,000 | $1,388,000 | 0.30% |